Steven Rosenfeld

Company: Mayo Clinic

Job title: Professor,Depts. Neurology, Medical Oncology & Pharmacology

Seminars:

MT-125 Inhibits Non-Muscle Myosin IIA & IIB, Synergizes with both Radiation & Oncogenic Kinase Inhibitors & Prolongs Survival in Glioblastoma 2:30 pm

MT-125 increases cytoplasmic ROS, induces DNA damage and ferroptosis, prolongs survival in murine GBM models as a monotherapy, and synergizes with radiation. MT-125 stimulates oncogenic kinase signaling in glioblastoma through a novel ROSdriven mechanism that induces oncogene addiction, creating synthetic lethality when it is combined with oncogenic kinase inhibitors. Combining MT-125 with an FDA-approved PDGFR…Read more

day: Conference Day 2

Panel Discussion: Addressing the Peaks & Troughs of the GBM Space: What is Promising & Where is Innovation Necessary? 9:00 am

Highlighting emerging therapies such as immunotherapy and personalized medicine showing potential in GBM treatment Discussing barriers such as the blood-brain barrier, tumor resistance, and high recurrence rates Exploring key areas for innovation, including diagnostics, drug delivery, and combination therapiesRead more

day: Conference Day 1